Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025British Journal of Haematology

Decoding the molecular drivers of TP53 ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYu WangXZXiaohui ZhangXHXiao‐Jun Huang

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals TP53 mutations influence clinical outcomes in acute myeloid leukaemia, suggesting venetoclax may improve prognosis.

Key Points

  • Better responses observed with venetoclax and hypomethylating agent in TP53-mutant acute myeloid leukaemia patients, indicating improved treatment efficacy.
  • Median overall survival was better for specific mutation types, with CEBPA bZIP showing 25.2 months vs. 13.8 months in comparisons.
  • Assessment of prognostic factors revealed RUNX1-RUNX1T1 fusion gene significantly influenced overall survival at a hazard ratio of 0.23.
  • Study highlights the importance of molecular characteristics in acute myeloid leukaemia, necessitating further investigation of TP53 mutation sites.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/6930dc78ea1aef094cca23a9https://doi.org/10.1111/bjh.70271
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1TP53-mutated AML and treatment outcomes in the era of hypomethylating agent/venetoclax therapy2025
  2. 2Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type2025 · 4 citations
  3. 3Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.2025 · 1 citations
  4. 4Characteristics and prognostic implications of <i>TP53</i> mutations in Chinese patients with myelodysplastic syndromes2025 · 3 citations
  5. 5Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations